Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2020

Aug 12, 2020

SELL
$7.4 - $14.64 $6.33 Million - $12.5 Million
-855,437 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$5.17 - $8.91 $4.42 Million - $7.62 Million
855,437 New
855,437 $7.11 Million

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $75.8M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Bio Impact Capital LLC Portfolio

Follow Bio Impact Capital LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bio Impact Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bio Impact Capital LLC with notifications on news.